Myriad Genetics is expanding access to its faster hereditary cancer testing to include patients diagnosed with ovarian and endometrial cancer, broadening the reach of its genetic testing services as the company focuses on identifying patients who may carry inherited cancer risks.
The announcement comes during Ovarian Cancer Awareness Month, placing greater attention on the need for timely testing among patients whose cancer diagnosis may be linked to inherited genetic changes. By extending access to faster testing, Myriad aims to help healthcare providers obtain relevant genetic information sooner and use those findings when considering patient care and family risk.
The expansion also adds momentum to the development of ovarian cancer diagnostics, an area that is gaining importance as healthcare providers seek better ways to understand inherited risk alongside a patient’s diagnosis and family history. Hereditary cancer testing can identify genetic variants that may influence cancer risk and can provide information that may be relevant to treatment decisions, preventive care and screening for relatives.
Faster Genetic Testing Expands Its Role in Hereditary Cancer Care
Hereditary cancer testing has become an increasingly important part of oncology care because some cancers are associated with inherited genetic mutations. Identifying those mutations can help physicians determine whether a patient’s cancer may have a hereditary component and whether other family members could also face elevated risk.
For ovarian and endometrial cancer patients, timely access to this information can be particularly important because genetic findings may influence how healthcare professionals approach ongoing management and risk assessment. The faster testing option from Myriad is intended to reduce delays in obtaining hereditary cancer information, giving providers an additional resource during the cancer care process.
The latest expansion is also significant from a diagnostics industry perspective. Cancer testing is moving beyond identifying the presence of disease toward understanding the biological and genetic factors that may have contributed to it. Genetic information can add another dimension to conventional pathology, imaging and clinical assessments.
For testing companies, speed is becoming an increasingly important consideration alongside accuracy and clinical usefulness. Faster results can help healthcare teams incorporate genetic information into discussions with patients without waiting for lengthy testing cycles.
The announcement follows Myriad’s broader efforts to expand its oncology diagnostic portfolio. The company has previously introduced RiskScore, an assessment designed to help healthcare providers make more proactive decisions related to cancer prevention. Myriad has also developed an updated version of RiskScore aimed at supporting personalised breast cancer screening.
These developments indicate a broader strategy focused on using genetic and risk information at different stages of cancer care. Rather than limiting testing to patients who already have a confirmed diagnosis, such tools can also support risk assessment and decisions around screening and prevention.
For the ovarian cancer diagnostics market, greater availability of hereditary testing could contribute to a more comprehensive approach to evaluating patients. The potential value extends beyond the individual receiving the test, since identifying an inherited variant may provide information that can be discussed with relatives who could also benefit from appropriate genetic counselling or screening.
Myriad Strengthens Oncology Testing Portfolio as Awareness Grows
The timing of the announcement is particularly relevant during Ovarian Cancer Awareness Month, when healthcare organizations and patient advocacy groups place additional focus on the disease and the importance of recognising risk factors.
Ovarian cancer remains challenging to detect because symptoms can be difficult to distinguish from those associated with other conditions. Genetic testing does not replace clinical evaluation, but it can provide information about inherited risk that may not be visible through routine diagnostic assessments.
The inclusion of endometrial cancer patients further broadens the potential reach of Myriad’s faster hereditary testing. Both ovarian and endometrial cancers can be relevant to discussions around inherited cancer susceptibility, making genetic information an important consideration for appropriate patients.
From a business standpoint, expanding testing access allows Myriad to address a larger segment of the oncology market while strengthening its position in hereditary cancer assessment. The company’s previous investments in risk assessment and personalised screening suggest an effort to build a connected portfolio covering prevention, risk identification and cancer management.
The wider diagnostics industry is also seeing increasing interest in tests that can provide actionable information earlier in the patient journey. As physicians gain access to more detailed genetic information, the role of diagnostics is expanding from confirming disease to helping guide decisions about screening, monitoring and potential inherited risk.
For healthcare providers, the practical impact of faster testing will depend on how efficiently genetic results can be integrated into clinical workflows and patient discussions. Genetic counselling and appropriate interpretation remain important components of hereditary cancer testing, particularly when results may have implications for a patient’s relatives.
Myriad’s latest move therefore represents more than an expansion into two additional patient groups. It reflects the growing expectation that genetic information should become more accessible within routine oncology care and that testing should be available when clinicians need it to support informed decisions.
As awareness of hereditary cancer continues to increase, ovarian cancer diagnostics and related genetic testing are likely to remain important areas of development. Myriad’s decision to extend faster hereditary testing to ovarian and endometrial cancer patients gives healthcare providers another tool for evaluating inherited risk while adding to the company’s expanding presence across the cancer diagnostics landscape.
Ref: https://tradersunion.com/news/companies/show/3263679-myriad-hereditary-cancer-expansion/
